Natco Pharma Limited

Type: Company
Name: Natco Pharma Limited (NATCO Pharma Limited)
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

GRANTING CL FOR DASATINIB

The Department of Industrial Policy and Promotion (DIPP) last week once again approached the health ministry with the request to grant a compulsory license (CL) for the cancer drug, Dasatinib, on the ground that it is unaffordable to several thousands ... [Published PharmaBiz - Aug 20 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Pharma Patent Ruling Pinches Opportunities in Emerging Markets

The decision by an Indian court not to grant a new patent to drug firm Novartis for a modified form of its cancer drug Glivec (known as Gleevec in the U.S.) was a heavy blow to the company. It may be more than that, though, as other pharmaceutical companies ... [Published AdvisorOne - Aug 19 2014]
First reported Aug 16 2014 - Updated Aug 16 2014 - 1 reports

Net sales rise at fastest pace in nine quarters [Mint, New Delhi :: ]

Aug. 16--MUMBAI -- Indian companies reported the fastest pace of expansion in net sales in nine quarters and the best net profit growth in 18 quarters in the three months ended 30 June, indicating that a corporate turnaround may be under way after two ... [Published BusinessWeek - Aug 16 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 2 reports

Sensex hovers around 25900; Midcap, Smallcap fall over 1.5%

12:55pm Wockhardt under pressureInvestors are dumping shares of Wockhardt after its April-June quarter earnings disappointed the street. The stock fell 4 percent as the drugmaker’s Q1 net profit plunged 94 percent mainly due to numerous US Food and Drug ... [Published Moneycontrol.com - Aug 13 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Sensex pares some gains; BHEL down over 6% on weak results

The Sensex, which slipped into negative territory after rising to 25,972.62, has emerged into the positive zone again and is currently up 27.35 points or 0.1% at 25,908.12. The Nifty index of the National Stock Exchange is up 8.90 points or 0.12% at ... [Published Sify - Aug 13 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

NATCO records Rs.33.46 crores profit for the First Quarter ended June 2014

.Hyderabad based NATCO Pharma Limited has recorded an aggregate of Rs.211.48 Crores in consolidated net revenues for the quarter ended on 30th June, 2014, as against Rs. 176.01 Crores during the same quarter last year, recording an increase of about 20%. ... [Published Noodls - Aug 13 2014]
First reported Aug 12 2014 - Updated Aug 13 2014 - 1 reports

Sensex trades 150 points higher; Tata Motors, NTPC gain

At 9.35am, the Sensex was trading higher by 0.58%, or 149.22 points, at 25,668.46 points. Photo: Hemant Mishra/MintMumbai: The 30-share bellwether BSE Sensex on Tuesday was trading 150 points higher, led by shares of auto companies.At 9.35am, the Sensex ... [Published Livemint.com - Aug 12 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 3 reports

Natco Pharma Q1 profit jumps 54% to Rs33.46 crore

Natco Pharma has at least half a dozen specialty generic drugs in the domestic market. Photo: AFPMumbai: Hyderabad-based cancer drug maker Natco Pharma Ltd. on Tuesday said it posted a 54% increase in net profit at Rs33.46 crore during the April-June ... [Published Livemint.com - Aug 12 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Stocks in news: Tata Motors, HUL, IDFC, Jain Irrigation

Results Today: Coal India , IOC , BPCL , Jaiprakash Associates , Tata Power , Sun Pharma , NMDC , Oil India , BHEL , Britannia , Wockhardt , Aditya Birla Nuvo, Apollo Hospital, Astrazeneca Pharma, BEML, Bhushan Steel, Engineers India, Essar Oil, Gillette ... [Published Moneycontrol.com - Aug 12 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Gilead Sciences prices Sovaldi in India at a tiny fraction of U.S. cost

India will get 'low income' pricing, starting at $900 instead of U.S. price of $84,000ShareToolsGilead's Sovaldi--Courtesy of GileadThe $84,000 U.S. treatment price that Gilead Sciences ($GILD) is charging for its hepatitis C drug Sovaldi has elicited ... [Published FiercePharma - Aug 07 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

More pharma firms trying to settle patent rows via talks

Cipla and F. Hoffmann-La Roche are in talks to settle the Tarceva patent infringement case that dates back to 2008. Photo: S. Kumar/MintMumbai: Indian generics or copycat drug makers and multinational pharma companies are increasingly resorting to mediation ... [Published Livemint.com - Jul 29 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Gilead Sciences, Inc. v. Natco Pharma Ltd. (Fed. Cir.)

Case Name: Gilead Sciences, Inc. v. Natco Pharma Ltd. , 2013-1418, 2014 U.S. App. LEXIS 7494 (Fed. Cir. Apr. 22, 2014) (Circuit Judges Rader, Prost, and Chen presiding; Opinion by Chen, J.; Dissent by Rader, C.J.) (appeal from D.N.J., Wigenton, J.)Drug ... [Published JD Supra - Jul 25 2014]

Quotes

...In the second instance, the Ministry said the CL should be granted for ` "public non commercial use' and that government schemes could help with the cost of producing the bloodblood cancer medicine. The Ministry added that it planned to use several schemes to fund the cost of making the drug to ensure its availability to needy patients. At that time, the DIPP ruled that the circumstances were not `grave' enough in the country to warrant a CL for dasatinib."
...Cancer Genetics," said Venkatadri Bobba, general partner of Ventureast, India's premier venture capital fund and a board member at BioServe India. "This merger will allow us to improve patient care in India by delivering cutting-edge, patented cancer diagnostic technologies and allow us to offer an even broader range of state-of-the-art services to biopharma customers, hospitals and academic research institutions."
"We now have a growing pipeline of potential clients and collaborators for our non-invasive cervical cancer test in India, where cervical cancer is the leading cause of cancer death in women, accounting for 25 percent of global cervical cancer deaths" Sharma said. "FHACT®
"The earnings may show a boost due to some sectors contributing hugely, mainly based on exports, and more so, some companies had posted losses last year in the same quarter" said Phani Sekhar, a fund manager at Angel Broking Pvt. Ltd

More Content

All (96) | News (81) | Reports (0) | Blogs (14) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
GRANTING CL FOR DASATINIB [Published PharmaBiz - Aug 20 2014]
3 Reasons Mylan Inc Stock Could Rise [Published Motley Fool - Aug 19 2014]
Indian Health Ministry seeking compulsory licen... [Published Pharma Letter - Aug 19 2014]
Pharma Patent Ruling Pinches Opportunities in E... [Published AdvisorOne - Aug 19 2014]
Cancer Genetics Inc completes BioServe India buy [Published Economic Times - Aug 18 2014]
Cancer Genetics Inc. Completes Acquisition of B... [Published EMoneyDaily - Aug 18 2014]
Net sales rise at fastest pace in nine quarters... [Published BusinessWeek - Aug 16 2014]
Punters make merry as bourses shift over 550 st... [Published Economic Times - Aug 15 2014]
Net sales rise at fastest pace in nine quarters [Published Livemint.com - Aug 15 2014]
Sensex hovers around 25900; Midcap, Smallcap fa... [Published Moneycontrol.com - Aug 13 2014]
NATCO records Rs.33.46 crores profit for the Fi... [Published Noodls - Aug 13 2014]
Sensex hovers around 25900; BSE Midcap, Smallca... [Published Moneycontrol.com - Aug 13 2014]
Sensex pares some gains; BHEL down over 6% on w... [Published Sify - Aug 13 2014]
Stocks in news: BHEL, Sun Pharma, ONGC, NMDC, E... [Published Moneycontrol.com - Aug 13 2014]
Natco Pharma Q1 profit jumps 54% to Rs33.46 crore [Published Livemint.com - Aug 12 2014]
Natco Pharma Q1 increases 53.62 per cent at Rs ... [Published Business Standard India - Aug 12 2014]
Natco Pharma Q1 net up 54% [Published Hindu Business Line - Aug 12 2014]
Stocks in news: Tata Motors, HUL, IDFC, Jain Ir... [Published Moneycontrol.com - Aug 12 2014]
Sensex trades 150 points higher; Tata Motors, N... [Published Livemint.com - Aug 12 2014]
Teva May Drag DRL to Court in Patent Row [Published New Indian Express - Aug 12 2014]
Teva may move court against Dr Reddy's for pate... [Published Business Standard India - Aug 11 2014]
Gilead Sciences prices Sovaldi in India at a ti... [Published FiercePharma - Aug 07 2014]
Stocks in news: Hero, Bata, Capital First, KRBL... [Published Moneycontrol.com - Aug 06 2014]
Sun Pharmaceutical's Dilip Shanghvi tops global... [Published Economic Times - Aug 04 2014]
Teva Raises Forecast as Profit Beats Estimates ... [Published Washington Post - Jul 31 2014]
Market on a positive wicket, corrections a good... [Published Economic Times - Jul 31 2014]
More pharma firms trying to settle patent rows ... [Published Livemint.com - Jul 29 2014]
Gilead Sciences, Inc. v. Natco Pharma Ltd. (Fed... [Published JD Supra - Jul 25 2014]
Indo-US Strategic Dialogue on Thursday; Kerry t... [Published Business Standard India - Jul 24 2014]
Pre-Filled Syringes Market (2nd Edition), 2014 ... [Published RCL Advisors - Jul 21 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Court Report [Published Patent Docs - Jun 01 2014]
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Cephalon Inc. v. Breckenridge Pharmaceutical Inc. et al. 1:14-cv-00671; filed May 27, 2014 in the District Court of Delaware•Plaintiff: ...
6 Drugs That Could Move the Market [Published Wall St. Cheat Sheet - Apr 29 2014]
Overview In the last few years, a number of promising drugs that treat serious conditions and diseases have come through drugmakers’ pipelines. Recent developments in oncology, for instance, mean that there are more promising, potential blockbuster ...
Gilead Sciences, Inc. v. Natco Pharma Ltd. (Fed... [Published Patent Docs - Apr 29 2014]
By Kevin E. Noonan -- The Federal Circuit extended the scope of the judicially created doctrine of obviousness-type double patenting (OTDP) in a split decision rendered in Gilead Sciences Inc. v. Natco Pharma Ltd. In doing so, the panel majority applied ...
Federal Circuit Rules for Axinn Client Natco Ph... [Published EON Business - Apr 25 2014]
HARTFORD, Conn.--(EON: Enhanced Online News)--A ruling by the U.S. Court of Appeals for the Federal Circuit has given Axinn, Veltrop & Harkrider LLP client Natco Pharma Ltd. a second chance at invalidating Gilead Sciences Inc.’s patent on the popular ...
Federal Circuit Rules for Axinn Client Natco Ph... [Published Business Wire Professional Services News - Apr 25 2014]
HARTFORD, Conn.--(BUSINESS WIRE)--A ruling by the U.S. Court of Appeals for the Federal Circuit has given Axinn, Veltrop & Harkrider LLP client Natco Pharma Ltd. a second chance at invalidating Gilead Sciences Inc.’s patent on the popular flu drug Tamiflu. ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.